RNAZ Transcode Therapeutics, Inc.: institutional ownership and insider trading
9 funds reported holding $208K of Transcode Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $16.4K, with 2 new positions and 2 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
RNAZ revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.75M, EPS -7.17
- Quarter ended Mar 31, 2026: revenue n/a, net income −$17.8M, EPS -21.28
- Quarter ended Dec 31, 2025: revenue n/a, net income −$13.4M, EPS 28.52
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.86M, EPS -5.82
Largest institutional holders of RNAZ
- Yorkville Advisors Global, LP — $122K
- VANGUARD CAPITAL MANAGEMENT LLC — $40.6K
- VANGUARD FIDUCIARY TRUST CO — $18.5K
- UBS Group AG (UBS) — $17.9K
- FMR LLC — $4.38K
- Tower Research Capital LLC (TRC) — $4.20K
- WELLS FARGO & COMPANY/MN (WFC, WFCNP, WFC-PA, WFC-PC, WFC-PD, WFC-PL, WFC-PY, WFC-PZ) — $342
- SBI Securities Co., Ltd. — $20
- IFP Advisors, Inc — $13
5%+ owners
- DEFJ, LLC: 83.9% (Schedule 13D/A, filed Aug 3, 2026)
- Unleash Immuno Oncolytics, Inc.: 9.9% (Schedule 13G, filed Jul 28, 2026)
- YA II PN, Ltd.: 9.9% (Schedule 13G, filed Apr 20, 2026)
- Elena Rosa Braci: 6.2% (Schedule 13G, filed Jul 28, 2026)
- Daniel Eduardo Katzman: 5.2% (Schedule 13G, filed Jul 28, 2026)
Who owns the most RNAZ stock?
The largest institutional holders of Transcode Therapeutics, Inc. in the latest 13F filings are Yorkville Advisors Global, LP ($122K), VANGUARD CAPITAL MANAGEMENT LLC ($40.6K), VANGUARD FIDUCIARY TRUST CO ($18.5K).
Are insiders buying or selling RNAZ?
No open-market insider buys or sells of Transcode Therapeutics, Inc. were reported in the last 12 months.